Fairfield, Bush & Co’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-7,000
| Closed | -$1.99M | – | 142 |
|
|
2023
Q2 | $1.99M | Hold |
7,000
| – | – | 0.55% | 41 |
|
|
2023
Q1 | $1.95M | Buy |
+7,000
| New | +$1.94M | 0.69% | 38 |
|
|
2021
Q4 | – | Sell |
-7,000
| Closed | -$1.98M | – | 134 |
|
|
2021
Q3 | $1.98M | Buy |
+7,000
| New | +$2.29M | 0.64% | 42 |
|
|
2021
Q2 | – | Sell |
-7,000
| Closed | -$1.96M | – | 149 |
|
|
2021
Q1 | $1.96M | Hold |
7,000
| – | – | 0.56% | 42 |
|
|
2020
Q4 | $1.71M | Hold |
7,000
| – | – | 0.5% | 47 |
|
|
2020
Q3 | $1.99M | Hold |
7,000
| – | – | 0.63% | 41 |
|
|
2020
Q2 | $1.87M | Hold |
7,000
| – | – | 0.67% | 41 |
|
|
2020
Q1 | $2.21M | Hold |
7,000
| – | – | 0.92% | 31 |
|
|
2019
Q4 | $2.08M | Hold |
7,000
| – | – | 0.76% | 38 |
|
|
2019
Q3 | $1.63M | Hold |
7,000
| – | – | 0.56% | 44 |
|
|
2019
Q2 | $1.64M | Hold |
7,000
| – | – | 0.56% | 44 |
|
|
2019
Q1 | $1.66M | Sell |
7,000
-3,000
| -30% | -$945K | 0.55% | 44 |
|
|
2018
Q4 | $3.01M | Hold |
10,000
| – | – | 1.04% | 26 |
|
|
2018
Q3 | $3.53M | Hold |
10,000
| – | – | 0.99% | 28 |
|
|
2018
Q2 | $2.9M | Hold |
10,000
| – | – | 0.85% | 32 |
|
|
2018
Q1 | $2.74M | Hold |
10,000
| – | – | 0.8% | 30 |
|
|
2017
Q4 | $3.19M | Hold |
10,000
| – | – | 0.88% | 31 |
|
|
2017
Q3 | $3.13M | Hold |
10,000
| – | – | 0.98% | 29 |
|
|
2017
Q2 | $2.71M | Hold |
10,000
| – | – | 0.87% | 31 |
|
|
2017
Q1 | $2.73M | Hold |
10,000
| – | – | 0.85% | 31 |
|
|
2016
Q4 | $2.84M | Hold |
10,000
| – | – | 0.92% | 31 |
|
|
2016
Q3 | $3.13M | Hold |
10,000
| – | – | 1.01% | 32 |
|
|
2016
Q2 | $2.42M | Hold |
10,000
| – | – | 0.84% | 36 |
|
|
2016
Q1 | $2.6M | Hold |
10,000
| – | – | 0.93% | 33 |
|
|
2015
Q4 | $3.06M | Buy |
+10,000
| New | +$2.87M | 1.07% | 35 |
|
|
2015
Q3 | – | Sell |
-10,000
| Closed | -$4.04M | – | 140 |
|
|
2015
Q2 | $4.04M | Hold |
10,000
| – | – | 1.21% | 31 |
|
|
2015
Q1 | $4.22M | Hold |
10,000
| – | – | 1.23% | 30 |
|
|
2014
Q4 | $3.4M | Hold |
10,000
| – | – | 0.97% | 37 |
|
|
2014
Q3 | $3.31M | Hold |
10,000
| – | – | 0.95% | 35 |
|
|
2014
Q2 | $3.15M | Buy |
+10,000
| New | +$3.01M | 0.93% | 37 |
|
|
2013
Q4 | – | Sell |
-10,000
| Closed | -$2.41M | – | 145 |
|
|
2013
Q3 | $2.41M | Hold |
10,000
| – | – | 0.73% | 45 |
|
|
2013
Q2 | $2.15M | Buy |
+10,000
| New | +$2.14M | 1.1% | 22 |
|
Other funds holding BIIB
Fairfield, Bush & Co's BIIB Position: Q3 2023 in Review
Fairfield, Bush & Co sold out of Biogen (BIIB) in Q3 2023, closing a stake of 7,000 shares — an estimated $1.99M sold.
Fairfield, Bush & Co first reported a position in BIIB in Q2 2013 and held it in 32 quarters. The position peaked at $4.22M in Q1 2015. 966 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.
- Fairfield, Bush & Co reported no remaining Biogen position as of Q3 2023 after selling out during the quarter.
- Fairfield, Bush & Co sold 7,000 Biogen shares in Q3 2023, an estimated $1.99M.
- Fairfield, Bush & Co first reported a position in Biogen in Q2 2013 and held it in 32 quarters.
- Fairfield, Bush & Co's Biogen position peaked at $4.22M in Q1 2015.
- 966 funds tracked by Wall St. Rank held Biogen as of Q3 2023.
Based on Fairfield, Bush & Co's 13F filing for Q3 2023, filed 15 Nov 2023.